<div id="readability-page-1"><div><p>Health-care companies fell sharply as traders rotated into sectors more sensitive to changes in interest rates.</p><p>    Halozyme was granted a preliminary injunction that would prevent Merck &amp; Co. from distributing a formulation of Keytruda in Germany as part of a patent-infringement dispute over the cancer treatment. </p><p>    The Trump administration's ambition to unleash biomedical innovation and sharpen America's edge against China is colliding with a far messier reality inside the Food and Drug Administration, as Robert F. Kennedy Jr.'s revamping of American public health policy has inspired infighting and staff turnover, The Wall Street Journal reported. </p><p>   Write to Rob Curran at rob.curran@dowjones.com </p><p>    (END) Dow Jones Newswires</p><p>12-04-25 1738ET</p></div></div>

HALO

<p>Health-care stocks fell sharply as traders shifted to rate-sensitive sectors. Halozyme secured a preliminary injunction against Merck & Co. in a patent dispute over Keytruda in Germany. The Trump administration's biomedical innovation goals face challenges within the FDA, amid infighting and staff turnover influenced by Robert F. Kennedy Jr.'s policy changes.</p>

Health Care Down Sharply on Rotation to Rate-Sensitive Sectors -- Health Care Roundup